Research Publications


OPEN ACCESS

USCLC/ISCL papers

  1. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders.
    Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, Olsen E, Kim YH, et al.
    Blood. 2011, 118: 4024-4035.
  2. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
    Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, et al.
    J Clin Oncol. 2011, 29: 2598-2607.
  3. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).
    Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, et al.
    J Am Acad Dermatol. 2011, 64: 352-404. Review.
  4. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).
    Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, Dummer R, Hoppe RT.
    Blood. 2007, 110: 479-484.
  5. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the ISCL and the cutaneous lymphoma task force of the EORTC.
    Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, et al.
    Blood. 2007, 110: 1713-1722.

CLF Summit meeting 2009

  1. The State of Cutaneous Lymphomas: A Call to Action
    Lessin S.R. and Porcu P.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S55-S58
  2. Outsmarting Cutaneous T-Cell Lymphoma Cells by Decoding the Language They Speak: Focusing Past and Present Insights on Future Prospects
    Edelson R.L.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S59-S62
  3. Trends in Cutaneous Lymphoma Epidemiology
    Markova A. and Weinstock M.A.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S63-S66
  4. Familial Mycosis Fungoides: Model of Genetic Susceptibility
    Hodak E. and Friedman E.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S67-S69
  5. What Can Psoriasis Teach Us About the Genetic Basis of Cutaneous T-Cell Lymphoma?
    Elder J.T.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S70-S73
  6. Lessons Learned From the Systematic Evaluation of Cutaneous T-Cell Lymphomas at the National Cancer Institute and the Roadmap for Future Studies
    Bunn, Jr. P.A. and Pacheco T.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S74-S79
  7. Rational Clinical Trial Design in Cutaneous Lymphoma
    Duvic M.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S80-S83
  8. New Strategies to Optimize Outcomes in Patients With T-Cell Lymphoma
    Zain J. and O'Connor O.A.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S84-S87
  9. The United States Cutaneous Lymphoma Consortium (USCLC)
    Olsen E.A.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S88-S89
  10. A Cutaneous T-Cell Lymphoma EORTC Trials Platform
    Whittaker S.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S90-S92
  11. Immune Modulators as Therapeutic Agents for Cutaneous T-Cell Lymphoma
    Rook A.H., Benoit B., Kim E.J., Vittorio C., Anshelevich A., Raphael B.A., Introcaso C.E., Gardner J.M. et al.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S93-S95
  12. Hematopoietic Stem Cell Transplantation for Cutaneous T-Cell Lymphoma
    Devine S.M.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S96-S98
  13. Radiation Therapy and Cutaneous Lymphoma
    Wilson L.D.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S99-S102
  14. Local Versus Systemic Treatment for Primary Cutaneous B-Cell Lymphoma
    Zinzani P.L., Argnani L. and Broccoli A. Clinical Lymphoma, Myeloma & Leukemia, Volume 10,
    Supplement 2, S103-S105
  15. Multidisciplinary Care in the Management of Patients With Cutaneous Lymphoma: A Perspective
    Kim Y.H.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S106-S108
  16. A Look at the National Comprehensive Cancer Network Guidelines for Cutaneous Lymphomas
    Porcu P.
    Clinical Lymphoma, Myeloma & Leukemia, Volume 10, Supplement 2, S109-S111